Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies

Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies

Chapter 1: Pathophysiology and Novel Mechanisms of Action

3 chapters
0.50 credits
30 minutes
Play All
CME/CE
ReachMD Healthcare Image
Media formats available:
Details
Program chapters
Presenters
Related
Comments
  • Overview

    Given the significant unmet burden in immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), there is a demonstrated need to diagnose patients earlier. This is particularly important in light of the significant lifetime risk of kidney failure faced by pediatric and young adult patients. This is your chance to join the experts as they discuss the limitations of current treatments and explore promising emerging therapies.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Jonathan Barratt, PhD
    The Mayer Professor of Renal Medicine
    University of Leicester
    Leicester, United Kingdom

    Research: argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Travere Therapeutics, Visterra
    Consulting Fees: Alnylam, argenx, Astellas, BioCryst, Calliditas, Chinook, Dimerix, Galapagos, Novartis, Omeros, Travere Therapeutics, Vera Therapeutics, Visterra

    Faculty:
    Donald E. Kohan, MD, PhD
    Emeritus Professor of Medicine
    Division of Nephrology
    University of Utah Health
    Salt Lake City, UT 

    Consulting Fees: Chinook, Travere

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William Mencia, MD, has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Demonstrate clinical reasoning in arriving at a diagnosis of immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)
    • Discuss current treatment limitations for patients with IgAN and FSGS
    • Review the mechanisms of action of endothelin receptor antagonists 
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

     

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Kidney Academy…
but how about a more personalized experience?

Register for free